Abstract

Aryl-hydrocarbon receptor (AhR) is a ligand-activated transcription factor and regulates differentiation and function of various immune cells such as dendritic cells, Th17, and regulatory T cells. In recent studies, it was reported that AhR is involved in bone remodeling through regulating both osteoblasts and osteoclasts. However, the roles and mechanisms of AhR activation in human osteoclasts remain unknown. Here we show that AhR is involved in human osteoclast differentiation. We found that AhR expressed highly in the early stage of osteoclastogenesis and decreased in mature osteoclasts. Kynurenine (Kyn), formylindolo[3,4-b] carbazole (FICZ), and benzopyrene (BaP), which are AhR agonists, inhibited osteoclast formation and Kyn suppressed osteoclast differentiation at an early stage. Furthermore, blockade of AhR signaling through CH223191, an AhR antagonist, and knockdown of AhR expression reversed Kyn-induced inhibition of osteoclast differentiation. Overall, our study is the first report that AhR negatively regulates human osteoclast differentiation and suggests that AhR could be good therapeutic molecule to prevent bone destruction in chronic inflammatory diseases such as rheumatoid arthritis (RA).

Highlights

  • We analyzed the relevance of Aryl-hydrocarbon receptor (AhR) in human osteoclast differentiation

  • AhR mRNA gradually decreased during osteoclast differentiation (Figure 1A)

  • To verify whether macrophage colony-stimulating factor (M-CSF) or RANKL is important for osteoclast differentiation that could regulate

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Osteoclast is a multinucleated giant cell derived from hematopoietic cell of the myeloid lineage. Receptor activators of nuclear factor kappa B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) produced by osteoblasts are essential cytokines for osteoclast differentiation and functions. M-CSF promotes formation of osteoclast precursors (OCPs) that express the RANK receptor for RANKL. When binding RANKL to RANK on OCPs, it differentiates into mature osteoclasts to have potent bone resorption activity [1,2]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.